NCT06055985: An ongoing trial by UCB Biopharma SRL
This trial is completed, but has been granted a delay in reporting its results.
It must report results 1 year, 9 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06055985 |
|---|---|
| Title | A Multicenter Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 17, 2023 |
| Completion date | March 31, 2025 |
| Required reporting date | March 31, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 19, 2026 |
| Days late | None |